Edwards Lifesciences Corporation $EW Shares Acquired by Saudi Central Bank

Key Points

• Saudi Central Bank increased its Edwards Lifesciences stake by 88.4% in the second quarter, acquiring 18,938 additional shares and bringing its holdings to 40,358 shares valued at approximately $3.65 million. Institutional investors and hedge funds collectively own 79.46% of the company.
• Analysts remain generally optimistic, with a consensus rating of “Moderate Buy” and an average price target of $100.27. Several firms recently raised their targets to as high as $110, although one analyst downgraded the stock to “hold.”
• Edwards Lifesciences reported quarterly earnings of $0.78 per share, beating estimates of $0.74, while revenue rose 13.6% year over year to $1.74 billion. The stock opened at $90.00, near its 50-day average of $89.73.

Saudi Central Bank boosted its position in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 88.4% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 40,358 shares of the medical research company's stock after buying an additional 18,938 shares during the quarter. Saudi Central Bank's holdings in Edwards Lifesciences were worth $3,651,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Pin Oak Investment Advisors Inc. bought a new stake in Edwards Lifesciences during the second quarter valued at $26,000. TrinityBridge Ltd acquired a new position in shares of Edwards Lifesciences during the 2nd quarter valued at $27,000. MV Capital Management Inc. bought a new position in Edwards Lifesciences during the fourth quarter valued at about $26,000. Hanson & Doremus Investment Management acquired a new position in shares of Edwards Lifesciences in the 1st quarter worth approximately $25,000. Finally, Kemnay Advisory Services Inc. bought a new position in shares of Edwards Lifesciences in the fourth quarter valued at $27,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, VP Daniel Lippis sold 619 shares of the stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total transaction of $56,966.57. Following the sale, the vice president owned 40,034 shares in the company, valued at approximately $3,684,329.02. This represents a 1.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 544 shares of the company's stock in a transaction dated Monday, August 31st. The stock was sold at an average price of $91.06, for a total transaction of $49,536.64. Following the transaction, the senior vice president owned 14,868 shares in the company, valued at approximately $1,353,880.08. This trade represents a 3.53% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 5,045 shares of company stock valued at $457,749. 0.31% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research analysts have commented on EW shares. Mizuho raised their target price on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the stock an "outperform" rating in a report on Wednesday, July 15th. BTIG Research lifted their price target on Edwards Lifesciences from $100.00 to $110.00 and gave the company a "buy" rating in a report on Tuesday, June 30th. Wall Street Zen cut shares of Edwards Lifesciences from a "buy" rating to a "hold" rating in a report on Saturday, July 4th. Citigroup upped their target price on Edwards Lifesciences from $101.00 to $110.00 and gave the stock a "buy" rating in a research report on Wednesday, July 8th. Finally, UBS Group assumed coverage on Edwards Lifesciences in a research note on Tuesday, July 28th. They issued a "buy" rating and a $110.00 price objective on the stock. Seventeen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $100.27.

Edwards Lifesciences Trading Up 0.1%

Shares of EW opened at $90.00 on Monday. The company has a current ratio of 4.52, a quick ratio of 3.77 and a debt-to-equity ratio of 0.06. The stock has a 50 day simple moving average of $89.73 and a 200-day simple moving average of $85.56. Edwards Lifesciences Corporation has a 1 year low of $72.30 and a 1 year high of $96.29. The stock has a market cap of $51.82 billion, a PE ratio of 51.72, a PEG ratio of 2.36 and a beta of 0.85.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its earnings results on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The company had revenue of $1.74 billion for the quarter, compared to the consensus estimate of $1.70 billion. During the same quarter in the previous year, the company earned $0.67 EPS. The firm's revenue for the quarter was up 13.6% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, sell-side analysts predict that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source